
WHAT IS CLAIMED IS:

Claim 1. A compound of Formula J:



(J)

or a pharmaceutically acceptable salt thereof, wherein

R^1 is heterocycloalkyl having 3 to 12 ring members and 1 to 4 heteroatoms each N, O or S, phenyl or heteroaryl having 5 to 10 ring members and 1 to 5 heteroatoms each N, O or S, each independently substituted with 0 to 5 R^{1a} groups;

each R^{1a} is independently C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxyalkyl, C_{1-6} hydroxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -OH, oxo, -CN, $-C(O)N(R^{1b})(R^{1c})$, C_{3-10} cycloalkyl, or heterocycloalkyl having 3 to 12 ring members and 1 to 4 heteroatoms each N, O or S;

each R^{1b} and R^{1c} is independently hydrogen, C_{1-6} alkyl or a 3 to 8 membered heterocycloalkyl having 1 to 3 heteroatoms each independently N, O or S;

A^1, A^2, A^3 and A^4 are each independently $=CR^2-$ or =N-;

each R^2 is independently hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, hydroxy or -CN;

L^2 is -C(O)-, -C(O)O-, $-C(O)N(R^3)-$, $-S(O)_2-$ or $-S(O)_2N(R^3)-$;

R^3 is hydrogen, or C_{1-6} alkyl;

R^4 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{2-6} alkoxyalkyl, C_{1-6} hydroxyalkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, C_{1-6} alkyl-C_{3-8} cycloalkyl, heterocycloalkyl, C_{1-6} alkyl-heterocycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, -O-C_{6-12} aryl, heteroaryl, or C_{1-6} alkyl-heteroaryl,

wherein each heterocycloalkyl independently has 3 to 12 ring members and 1 to 3 heteroatoms each independently N, O or S,

wherein each heteroaryl independently has 5 to 10 ring members and 1 to 4 heteroatoms each independently N, O or S, and

wherein the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each independently substituted with 0 to 5 R^{4a} groups;

alternatively, R^3 and R^4 are combined with the atoms to which they are attached to form a heterocycloalkyl having 3 to 12 ring members and 1 to 3 additional heteroatoms each independently N, O or S, wherein the heterocycloalkyl is substituted with 0, 1 or 2 C_{1-6} alkyl groups;

each R^{4a} is independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, C_{1-6} hydroxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, -OH, oxo, $-C(O)R^{4b}$, $-C(O)OR^{4b}$, $-OC(O)R^{4b}$, $-OC(O)OR^{4b}$, $-C(O)N(R^{4b})(R^{4c})$, $-N(R^{4b})C(O)R^{4c}$, $-OC(O)N(R^{4b})(R^{4c})$, $-N(R^{4b})C(O)OR^{4c}$, $-S(O)_2R^{4b}$, $-S(O)_2N(R^{4b})(R^{4c})$, $-N(R^{4b})S(O)_2R^{4c}$, C_{3-8} cycloalkyl, C_{1-6} alkyl-C_{3-8} cycloalkyl, heterocycloalkyl, C_{1-6} alkyl-heterocycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, -O-C_{6-12} aryl, heteroaryl, or C_{1-6} alkyl-heteroaryl, wherein each heterocycloalkyl independently has 3 to 12 ring members and 1 to 3 heteroatoms each independently N, O or S, wherein each heteroaryl independently has 5 to 10 ring members and 1 to 4 heteroatoms each independently N, O or S, and wherein each cycloalkyl, heterocycloalkyl, aryl and heteroaryl is substituted with 0, 1 or 2 C_{1-6} alkyl groups;

each R^{4b} and R^{4c} is hydrogen or C_{1-6} alkyl;

R^5 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{2-6} alkoxyalkyl, C_{1-6} hydroxyalkyl, C_{1-6} haloalkyl, C_{1-6} alkyl-OR^{5a}, $-C(O)R^{5a}$, C_{1-6} alkyl-$C(O)R^{5a}$, $-C(O)OR^{5a}$, $-C(O)N(R^{5a})(R^{5b})$, $-S(O)_2R^{5a}$, $-S(O)_2N(R^{5a})(R^{5b})$, C_{3-8} cycloalkyl, C_{1-6} alkyl-C_{3-8} cycloalkyl, heterocycloalkyl, C_{1-6} alkyl-heterocycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heteroaryl, or C_{1-6} alkyl-heteroaryl,

wherein each heterocycloalkyl independently has 3 to 12 ring members and 1 to 3 heteroatoms each independently N, O or S,

wherein each heteroaryl independently has 5 to 10 ring members and 1 to 4 heteroatoms each independently N, O or S, and

wherein each cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently substituted with 0 to 4 R^{5c} groups;

each R^{5a} and R^{5b} is independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{2-6} alkoxyalkyl, hydroxy, C_{1-6} hydroxyalkyl, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-8} cycloalkyl, C_{1-6} alkyl-C_{3-8} cycloalkyl, heterocycloalkyl, C_{1-6} alkyl-heterocycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heteroaryl, or C_{1-6} alkyl-

heteroaryl, wherein each heterocycloalkyl independently has 3 to 12 ring members and 1 to 3 heteroatoms each independently N, O or S, wherein each heteroaryl independently has 5 to 10 ring members and 1 to 4 heteroatoms each independently N, O or S, and wherein each cycloalkyl, heterocycloalkyl, aryl and heteroaryl is subsituted with 0 to 4 R^{5d} groups;

alternatively, R^{5a} and R^{5b} are combined with the atoms to which they are attached to form a heterocycloalkyl having 3 to 12 ring members and 1 to 3 additional heteroatoms each independently N, O or S, wherein the heterocycloalkyl is substituted with 0, 1 or 2 C_{1-6} alkyl groups;

each R^{5c} is independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, C_{1-6} hydroxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, oxo, -OH, $-C(O)R^{5c1}$, $-C(O)OR^{5c1}$, $-OC(O)R^{5c1}$, $-OC(O)OR^{5c1}$, $-C(O)N(R^{5c1})(R^{5c2})$, $-N(R^{5c1})C(O)R^{5c2}$, $-OC(O)N(R^{5c1})(R^{5c2})$, $-N(R^{5c1})C(O)OR^{5c2}$, $-S(O)_2R^{5c1}$, $-S(O)_2N(R^{5c1})(R^{5c2})$, $-N(R^{5c1})S(O)_2R^{5c2}$, C_{3-8} cycloalkyl, C_{1-6} alkyl-C_{3-8} cycloalkyl, heterocycloalkyl, C_{1-6} alkyl-heterocycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heteroaryl, or C_{1-6} alkyl-heteroaryl, wherein each heterocycloalkyl independently has 3 to 12 ring members and 1 to 3 heteroatoms each independently N, O or S, wherein each heteroaryl independently has 5 to 10 ring members and 1 to 4 heteroatoms each independently N, O or S, and wherein each heterocycloalkyl and heteroaryl is substituted with 0, 1 or 2 C_{1-6} alkyl groups;

each R^{5c1} and R^{5c2} is independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{2-6} alkoxyalkyl, C_{1-6} hydroxyalkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, C_{1-6} alkyl-C_{3-8} cycloalkyl, heterocycloalkyl, C_{1-6} alkyl-heterocycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heteroaryl, or C_{1-6} alkyl-heteroaryl, wherein each heterocycloalkyl independently has 3 to 12 ring members and 1 to 3 heteroatoms each independently N, O or S, wherein each heteroaryl independently has 5 to 10 ring members and 1 to 4 heteroatoms each independently N, O or S, and wherein each heterocycloalkyl and heteroaryl is substituted with 0, 1 or 2 C_{1-6} alkyl groups;

alternatively, R^{5c1} and R^{5c2} are combined with the atoms to which they are attached to form a heterocycloalkyl having 3 to 12 ring members and 1 to 3 heteroatoms each independently N, O or S, wherein the heterocycloalkyl is substituted with 0, 1 or 2 C_{1-6} alkyl groups;


each R^{5d} is independently C_{1-6} alkyl or halogen;

each R^6 is independently hydrogen, C_{1-6} alkyl, halogen, C_{1-6} haloalkyl, or oxo;


subscript m is 0, 1, 2, 3, 4, or 5; and

subscript n is 1 or 2.

Claim 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is



Claim 3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R^1 is



Claim 4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein

A^1, A^2 and A^4 are each =CH-; and

A^3 is =C(Me)-, =C(OMe)-, =C(F)-, =C(Cl)-, or =C(CF_3)-.

Claim 5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein


A^1, A^2 and A^4 are each =CH-; and

A^3 is =C(Me)-.

Claim 6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein L^2 is -C(O)-, -$S(O)_2$- or -$S(O)_2N(Me)$-.

Claim 7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein L^2 is -$S(O)_2$-.

Claim 8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, having the structure of Formula Ic:



(Ic) .


Claim 9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein


R^4 is pyridine, pyrazole, thiazole, or triazole, each substituted with 0 to 2 R^{4a} groups; and

each R^{4a} is independently methyl, ethyl, n-propyl, iso-propyl, methoxy, methoxyethyl, fluoro, -CHF_2, -CF_3, -CH_2CHF_2, -CH_2CF_3, -CN, or tetrahydropyran.

Claim 10. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein


R^4 is methyl, n-propyl, iso-butyl, -CH(OH)CH_3, methoxyethyl, isopropoxyethyl, CH_2CF_3,






Claim 11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein


R^5 is ethyl, iso-propyl, iso-butyl,





Claim 12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein

R^1 is



; A^1, A^2 and A^4 are each =CH-;

A^3 is =C(Me)-;

L^2 is $-S(O)_2-$;

R^4 is pyridine, pyrazole, thiazole, or triazole, each substituted with 0 to 2 R^{4a} groups;

each R^{4a} is independently methyl, ethyl, n-propyl, iso-propyl, methoxy, methoxyethyl, fluoro, $-CHF_2$, $-CF_3$, $-CH_2CHF_2$, $-CH_2CF_3$, -CN, or tetrahydropyran;

R^5 is C_{1-6} alkyl, C_{1-6} haloalkyl, or C_{1-2} alkyl-C_{3-6} cycloalkyl, wherein each cycloalkylnis independently substituted with 0 to 2 R^{5c} groups;


each R^{5c} is independently C_{1-3} alkyl, C_{1-3} alkoxy, halogen, C_{1-3} haloalkyl, –CN, oxo or –OH;

subscript m is 0; and

subscript n is 1.

Claim 13. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein

R^1 is



;

A^1, A^2 and A^4 are each =CH-;

A^3 is =C(Me)-;

L^2 is $-S(O)_2-$;

R^4 is pyrazole or triazole, each substituted with 1 R^{4a} groups;

R^{4a} is methyl, ethyl, n-propyl, or iso-propyl;


R^5 is C_{1-6} haloalkyl;


subscript m is 0; and

subscript n is 1.

Claim 14. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein

R^1 is







A^1, A^2 and A^4 are each =CH-;

A^3 is =C(Me)-, =C(OMe)-, =C(F)-, =C(Cl)-, or =C(CF_3)-;


L^2 is –C(O)-, –$S(O)_2$- or –$S(O)_2$N(Me)-;


R^4 is methyl, n-propyl, iso-butyl, -CH(OH)CH_3, methoxyethyl, isopropoxyethyl, CH_2CF_3,





R^5 is ethyl, iso-propyl, iso-butyl,






















R^6 is hydrogen, methyl, or oxo; and





subscript m is 0, 1 or 2.







Claim 15. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, having the structure:







	;
	;
	;










	;
 Or 	;
 Or 	;
	;
	;






	;
 Or 	;
 Or 	;
	;
	;






	;
	;
	;
	;








	;
	;
	;
	;
	;
	;








	;
	;
	;
	;
	;
	;







 Or	;
 Or 	;
 Or 	;
 Or 	;
	;
	;





	;
	;
	;
	;
	;







	;
	;
	;
	;
	;














	;
	;
	;
	;
	;
	;
	;







 Or	;
 Or	;
 Or	;
 Or	;
 Or	;
 Or	;
 Or	;








	;
	;
	;
	;
	;
	;








	;
	;
	;
	;





	;
	;
	;
	;
	;
	;






 Or	;
 Or 	;
 Or 	;
 Or 	;
 Or 	;
 Or 	;
 Or 	;









 Or	;
 Or	;
 Or	;
	;
	;
	;





	;
	;
	;
	;
	;
	;
	;





	;
	;
	;
	;
	;
	;
	;





	;
	;
	;
	;





	;
	;
	;
	;
	;





 Or 	;
 Or 	;
 Or 	;
 Or 	;









	;
	;
	;
	;









	;
	;
	;
	;





	;
	;
	;
	;






	;
	;
	;
	;













	;
	;
	;
	;









 Or 	;
 Or 	;
 Or 	;
 Or 	;






 Or 	;
 Or 	;
 Or 	;
 Or 	;






	;
	;
	;
	;







 Or	;
 Or 	;
	;
	;










 Or  Or  Or 	;
 Or  Or  Or 	;
 Or 	;
 Or 	;











 And And Or  	;
	;
 Or 	;
 Or 	;









	;
	;
	;
	;
	;





	;
	;
	;
	;
	;





 Or 	;
 Or 	;
	;
	;





	;
 Or 	;
 Or 	;
 Or 	;
 Or 	;





 Or 		;
 Or 		;
 Or 		;
 Or 		;
 Or 		;





 Or 	;
 Or 	;
 Or 	;
	;
	;





	;
	;
	;
	;


	;
	;
	;
	;

	;
	;
	;
	;

	;
	;
	;
	;


	;
	;
	;
	;

	;
	;
	;
	; or




.


Claim 16. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, is the compound having the structure:





,






,







,




Or

,




,


Or

,




Or

,



Or

,



Or

,


And

And


Or




,






,
















, or





,



,

,

,

,

,

,


,

,

,

, or

.

Claim 17. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, is the compound having the structure



Or

.

Claim 18. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, is the compound having the structure




.

Claim 19. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, is the compound having the structure



.

Claim 20. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, is the compound having the structure



.

Claim 21. A pharmaceutical composition comprising a compound of any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

Claim 22. A compound of any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 21, for use in a method of treating a disorder or condition through modulating or antagonizing a glucocorticoid receptor.

Claim 23. The compound or pharmaceutical composition for use of claim 22, wherein the disorder or condition is selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis (ALS), antipsychotic induced weight gain, cancer, Cushing Disease, Cushing's Syndrome, major psychotic depression, Nonalcoholic steatohepatitis, and obesity.

Claim 24. Use of a compound of any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 21, in the manufacture of a medicament for treating a disorder or condition through modulating a glucocorticoid receptor.

Claim 25. Use of claim 24, wherein the disorder or condition is selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis (ALS), antipsychotic induced weight gain, cancer, Cushing Disease, Cushing's Syndrome, major psychotic depression, Nonalcoholic steatohepatitis, and obesity.